Benzinga | Oct 9, 2020 10:15AM EDT

Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy at ASN Kidney Week

* Results demonstrate a greater than 65% mean reduction in proteinuria at week 48 in C3G patients treated with pegcetacoplan

* Sustained improvements were seen across key clinical measures at 48 weeks

* There are no approved medicines for C3G, a rare disease that often leads to kidney failure